Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: A rational approach to second-generation Amadorin design

Annals of the New York Academy of Sciences

Volumn 1043, Issue , 2005, Pages 793-806

  Khalifah, Raja G ^a   Chen, Ying ^a   Wassenberg, James J ^a  

^a BioStratum Incorporated   (United States)

Author keywords

Amadori; Aminoguanidine; BST 4997; AGE inhibitors; Fructosyllysine; Pimagedine; Pyridorin; Pyridoxamine; Rational drug design

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT INHIBITOR; AMADORIN; AMINOGUANIDINE; ANTIOXIDANT; BST 4997; CARBOXYMETHYLLYSINE; FRUCTOSYLLYSINE; LYSINE DERIVATIVE; PYRIDORIN; PYRIDOXAMINE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; GLYCATION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PROTEIN GLYCOSYLATION; RENAL PROTECTION;

EID: 23744516038     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1333.092     Document Type: Conference Paper

References (41)

1. MONNIER, V.M. 2003. Intervention against the Maillard reaction in vivo. Arch. Biochem. Biophys. 419: 1-15.
2. WELLS-KNECHT, M.C., S.R. THORPE & J.W. BAYNES. 1995. Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry 34: 15134-15141.
3. BAYNES, J.W. & V.M. MONNIER. 1989. The Maillard Reaction in Aging, Diabetes and Nutrition. Alan R. Liss, Inc. New York.
4. BROWNLEE, M., H. VLASSARA, A. KOONEY, et al. 1986. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632.
5. BOLTON, W.K., D.C. CATTRAN, M.E. WILLIAMS, et al. 2004. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 24: 32-40.
6. KHALIFAH, R.G., P. TODD, A.A. BOOTH, et al. 1996. Kinetics of nonenzymatic glycation of ribonuclease A leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-Amadori studies. Biochemistry 35: 4645-4654.
7. BOOTH, A.A., R.G. KHALIFAH, P. TODD & B.G. HUDSON. 1997. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J. Biol. Chem. 272: 5430-5437.
8. WILLIAMS, M.E., W.K. BOLTON, T.P. DEGENHARDT & R. SCHOTZINGER. 2003. A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR-206)(Abstr.). J. Am. Soc. Nephrol. 14: 7A.
9. BELL, D.S.H., T.P. DEGENHARDT, J.R. SZABO, et al. 2004. Investigation of the safety and efficacy of pyridoxamine (Pyridorin™) in patients with diabetic nephropathy (PYR-206) (Abstr.). Diabetes 53(Suppl. 2): A119.
10. MCGILL, J.B., T.P. DEGENHARDT, J.R. SZABO, et al. 2004. A phase 2 clinical investigation of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR-205/207) (Abstr.). Diabetes 53(Suppl. 2): A138.
11. DEGENHARDT, T.P., N.L. ALDERSON, D.D. ARRINGTON, et al. 2002. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 61: 939-950.
12. STITT, A., T.A. GARDINER, N.L. ALDERSON, et al. 2002. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51: 2826-2832.
13. LECLERCQ, B., F. ZHENG, M. BERHO, et al. 2003. Decreased mortality and albuminuria following pyridoxamine and enalapril therapy in an obese mouse model of type 2 diabetes mellitus with established nephropathy (Abstr.). J. Am. Soc. Nephrol. 14: 396A.
14. CAMERON, N., M. COTTER, N. ALDERSON, et al. 2003. Pyridoxamine treatment improves nerve function in diabetic rats (Abstr.). Diabetes 52(Suppl. 1): A192.
15. KHALIFAH, R.G., J.W. BAYNES & B.G. HUDSON. 1999. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem. Biophys. Res. Commun. 257: 251-258.
16. REYNOLDS, T.M. 1963. Chemistry of nonenzymic browning. I. The reaction between aldoses and amines. Adv. Food Sci. 12: 1-52.
17. JANUSZEWSKI, A.S., N.L. ALDERSON, T.O. METZ, et al. 2003. Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem. Soc. Trans. 31: 1413-1416.
18. THORNALLEY, P.J., M. WESTWOOD, T.W. LO & A.C. MCLELLAN. 1995. Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes. Contrib. Nephrol. 112: 24-31.
19. THORNALLEY, P.J., A. LANGBORG & H.S. MINHAS. 1999. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 344: 109-116.
20. BROWNLEE, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
21. CHEN, H.J. & A. CERAMI. 1993. Mechanism of inhibition of advanced glycosylation by aminoguanidine in vitro. J. Carbohyd. Res. 12: 731-742.
22. THORNALLEY, P.J. 2003. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch. Biochem. Biophys. 419: 31-40.
23. FU, M.X., K.J. WELLS-KNECHT, J.A. BLACKLEDGE, et al. 1994. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43: 676-683.
24. GLOMB, M.A. & V.M. MONNIER. 1995. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J. Biol. Chem. 270: 10017-10026.
25. MONNIER, V.M. & A. CERAMI. 1981. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 211: 491-493.
26. MONNIER, V.M., V.J. STEVENS & A. CERAMI. 1981. Maillard reactions involving proteins and carbohydrates in vivo: relevance to diabetes mellitus and aging. Prog. Food Nutr. Sci. 5: 315-327.
27. REDDY, S., J. BICHLER, K.J. WELLS-KNECHT, et al. 1995. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878.
28. VOZIYAN, P.A., R.G. KHALIFAH, C. THIBAUDEAU, et al. 2003. Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J. Biol. Chem. 278: 46616-46624.
29. VOZIYAN, P.A., T.O. METZ, J.W. BAYNES & B.G. HUDSON. 2002. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J. Biol. Chem. 277: 3397-3403.
30. NAGARAJ, R.H., P. SARKAR, A. MALLY, et al. 2002. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch. Biochem. Biophys. 402: 110-119.
31. ALDERSON, N.L., M.E. CHACHICH, N. FRIZZELL, et al. 2004. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia 47: 1385-1395.
32. METZ, T.O., N.L. ALDERSON, S.R. THORPE & J.W. BAYNES. 2003. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch. Biochem. Biophys. 419: 41-49.
33. WOLFF, S.P. & R.T. DEAN. 1987. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem. J. 245: 243-250.
34. WELLS-KNECHT, K.J., D.V. ZYZAK, J.E. LITCHFIELD, et al. 1995. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34: 3702-3709.
35. ZYZAK, D.V., J.M. RICHARDSON, S.R. THORPE & J.W. BAYNES. 1995. Formation of reactive intermediates from Amadori compounds under physiological conditions. Arch. Biochem. Biophys. 316: 547-554.
36. DEGENHARDT, T.P., S.R. THORPE & J.W. BAYNES. 1998. Chemical modification of proteins by methylglyoxal. Cell. Mol. Biol. (Noisy-le-grand) 44: 1139-1145.
37. THORNALLEY, P.J. 2003. The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the concept. Biochem. Soc. Trans. 31: 1341-1342.
38. BROCK, J.W., D.J. HINTON, W.E. COTHAM, et al. 2003. Proteomic analysis of the site specificity of glycation and carboxymethylation of ribonuclease. J. Proteome Res. 2: 506-513.
39. SUNDBERG, R.J. & R.B. MARTIN. 1974. Interactions of histidine and other imidazole derivatives with transition metal ions in chemical and biological systems. Chem. Rev. 74: 471-517.
40. SIVITZ, W., O. BAUTISTA, P.A. CLEARY, et al. 2004. Skin collagen glycation products predict the progression risk of diabetic retinopathy and nephropathy in the Epidemiology of Diabetes Interventions and Complications Study (EDIC)(Abstr.). Diabetes 53(Suppl. 2): A58.
41. CAMERON, N.E., M.A. COTTER, Y. CHEN & R. KHALIFAH. 2004. Correction of neurovascular dysfunction in diabetic rats by the novel non-nucleophilic advanced glycation inhibitor, BST4997 (Abstr.). Diabetes 53(Suppl. 2): A209.